Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide, affecting both adults and children and will result, in the near future, as the leading cause of end-stage liver disease. Indeed, its prevalence is rapidly increasing, and NAFLD is becoming a major public health concern. For this reason, great efforts are needed to identify its pathogenetic factors and new therapeutic approaches. In the past decade, enormous advances understanding the gut–liver axis—the complex network of cross-talking between the gut, microbiome and liver through the portal circulation—have elucidated its role as one of the main actors in the pathogenesis of NAFLD. Indeed, evidence shows that gut microbiota is involved in the development and progression of liver steatosis, inflammation and fibrosis seen in the context of NAFLD, as well as in the process of hepatocarcinogenesis. As a result, gut microbiota is currently emerging as a non-invasive biomarker for the diagnosis of disease and for the assessment of its severity. Additionally, to its enormous diagnostic potential, gut microbiota is currently studied as a therapeutic target in NAFLD: several different approaches targeting the gut homeostasis such as antibiotics, prebiotics, probiotics, symbiotics, adsorbents, bariatric surgery and fecal microbiota transplantation are emerging as promising therapeutic options.

Fianchi, F., Liguori, A., Gasbarrini, A., Grieco, A., Miele, L., Nonalcoholic fatty liver disease (Nafld) as model of gut–liver axis interaction: From pathophysiology to potential target of treatment for personalized therapy, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2021; 22 (12): 6485-6485. [doi:10.3390/ijms22126485] [http://hdl.handle.net/10807/206444]

Nonalcoholic fatty liver disease (Nafld) as model of gut–liver axis interaction: From pathophysiology to potential target of treatment for personalized therapy

Fianchi, F.;Liguori, A.;Gasbarrini, A.;Miele, L.
2021

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide, affecting both adults and children and will result, in the near future, as the leading cause of end-stage liver disease. Indeed, its prevalence is rapidly increasing, and NAFLD is becoming a major public health concern. For this reason, great efforts are needed to identify its pathogenetic factors and new therapeutic approaches. In the past decade, enormous advances understanding the gut–liver axis—the complex network of cross-talking between the gut, microbiome and liver through the portal circulation—have elucidated its role as one of the main actors in the pathogenesis of NAFLD. Indeed, evidence shows that gut microbiota is involved in the development and progression of liver steatosis, inflammation and fibrosis seen in the context of NAFLD, as well as in the process of hepatocarcinogenesis. As a result, gut microbiota is currently emerging as a non-invasive biomarker for the diagnosis of disease and for the assessment of its severity. Additionally, to its enormous diagnostic potential, gut microbiota is currently studied as a therapeutic target in NAFLD: several different approaches targeting the gut homeostasis such as antibiotics, prebiotics, probiotics, symbiotics, adsorbents, bariatric surgery and fecal microbiota transplantation are emerging as promising therapeutic options.
Inglese
Fianchi, F., Liguori, A., Gasbarrini, A., Grieco, A., Miele, L., Nonalcoholic fatty liver disease (Nafld) as model of gut–liver axis interaction: From pathophysiology to potential target of treatment for personalized therapy, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2021; 22 (12): 6485-6485. [doi:10.3390/ijms22126485] [http://hdl.handle.net/10807/206444]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/206444
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 16
social impact